Bone Abstracts

Osteoporosis is an age related disease characterised by a progressive decrease of bone mineral density and loss of bone quality. Twin studies show that genetic component contributes up to 85% of the BMD variability of population. Surprisingly little variability of BMD can be explained by genetic polymorphisms (~2.9%). This highlights the complex genetic architecture and suggests that many other molecular processes and genes have to be involved. Our previous research showed tha...

Introduction: Mortality after hip fracture is increased. However, only a few studies have explored for predictors beyond gender and age. Thus our aim was to study risk factors associated with increased mortality in hip fracture patients.Methods: Hip fracture patients (>50 years) admitted to a county hospital in 2004–2005 were consecutively invited for assessment at the hospital osteoporosis centre. A broad spectre of data was collected. Standard...

Introduction and objective: Despite recent improvements in therapeutic management of osteosarcoma, ongoing challenges in improving the response to chemotherapy warrants the development of new strategies to improve overall patient survival. Among new therapeutic approaches, heat shock protein (HSP) 90 is a molecular chaperone involved in the maturation and stability of various oncogenic proteins leading to tumor cells survival. In this study, we assessed the in vitro a...

Introduction: Prostaglandin E2 has bone-anabolic effects through EP4 receptor but its clinical utility is hindered by gastrointestinal side effects. To avoid these side effects, EP4 agonists (EP4a) were covalently linked to the bisphosphonate alendronate (ALN) to create two ALN-EP4a conjugate drugs, C1 and C2. When administered systemically, C1 and C2 will be target delivered to bone through ALN, where local hydrolytic enzymes liberate EP4a from ALN to exert bone an...

Maternal vitamin D status has been positively associated with infant bone mass in observational studies. We therefore evaluated whether 1000 IU/day cholecalciferol during pregnancy would lead to greater offspring bone mass at birth, in a UK, multicentre, randomised, double-blind, placebo-controlled trial (MAVIDOS, ISRCTN82927713).At 12 weeks’ gestation, pregnant women with a serum 25-hydroxyvitamin D [25(OH)D] 25-100 nmol/l were randomised to either...

Objectives: AIS is a prevalent three-dimensional spinal deformity associated with low bone mass which has been reported to be a significant prognostic factor for curve progression in AIS. If left untreated, low bone mass in AIS could persist into adulthood thus leading to subsequent health problems. This study aimed at evaluating the therapeutic effect of oral calcium plus Vit-D supplementation for low bone mass in skeletally immature AIS girls.Methods: ...

Tenofovir disoproxil fumarate (TDF) is a critical component of first-line antiretroviral regimens for HIV worldwide. However, TDF-containing regimens have been associated with decreased bone mineral density and increased fracture risk, which may in part be mediated through secondary elevations in parathyroid hormone (PTH). Prior cross-sectional data suggest vitamin D binding protein (DBP) levels may increase with TDF exposure leading to a functional vitamin D deficiency, which...

Osteoporosis has a complex etiology and is considered a multifactorial polygenic disease in which genetic determinants are modulated by hormonal, environmental, and nutritional factors.Polymorphism of the vitamin D receptor gene has been reported to play a major role in variations for genetic regulation of bone mass but its role within various ethnic populations is not clear. Estrogens are known to play an important role in regulating bone homeostasis, t...

Background: Zoledronic acid (ZA) for the treatment of osteoporosis (OP) is associated with a transient post-infusional acute phase reaction (APR) due to ZA-mediated activation of γ-δ TCR lymphocytes (γ-δTCR) and production of cytokines.Primary objective: To investigate if OP patients developing APR (APR+) after ZA infusion have lower 25-OH vitamin D (25-OHvD) levels and a higher percentage of γ-δTCR compared to patients with...

Objectives: X-linked hypophosphataemia (XLH) is a rare, inherited, genetic disease characterised by renal phosphate wasting, bone mineralisation defects, rickets, abnormal tooth development, poor growth and, often, bone pain. Common treatment of children involves supplementation with oral phosphate and active vitamin D (often termed ‘conventional therapy’). The objective of this study was to identify and understand the perceived limitations of conventional therapy fo...